StreetInsider.com News Articles

JPMorgan Starts C4 Therapeutics (CCCC) at Overweight

Fri, 09 Oct 2026 03:22:50 -0400

JPMorgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Overweight rating and a price target of $10.00.

The analyst comments: “We are initiating coverage of C4 Therapeutics (CCCC) with an Overweight rating and a December 2027 price target of $10, driven by the potential of lead asset cemsidomide (cereblon-based IKZF1 / IKZF3 degrader) in multiple myeloma (MM). Indeed, despite a rapidly evolving treatment and development landscape, our key opinion leader (KOL) feedback suggests an emerging / additive clinical profile for cemsidomide in MM, supported by early phase 1 data in a highly refractory population. Of note, we

JPMorgan Starts C4 Therapeutics (CCCC) at Overweight

Fri, 09 Oct 2026 03:22:50 -0400

JPMorgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Overweight rating and a price target of $10.00.

Form 4 C4 Therapeutics, Inc. For: Oct 01 Filed by: Anderson Kenneth Carl

Fri, 02 Oct 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20261002/27143083.html

Form 4 C4 Therapeutics, Inc. For: Oct 01 Filed by: GROGAN DONNA ROY

Fri, 02 Oct 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20261002/27143080.html

Form 8-K C4 Therapeutics, Inc. For: Sep 25

Fri, 25 Sep 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260925/27104122.html

C4 Therapeutics shares cemsidomide biomarker data at myeloma meeting

Fri, 25 Sep 2026 07:00:15 -0400

C4 Therapeutics, Inc. (Nasdaq: CCCC) presented new biomarker data from two clinical trials of cemsidomide in relapsed/refractory multiple myeloma at the 23rd International Myeloma Society Annual Meeting on Sept. 25, 2026.

Data from the Phase 1 trial of cemsidomide combined with dexamethasone, involving 62 heavily pre-treated patients, showed T-cell activation, including CD8+ T cells, and functional reprogramming of natural killer cells. Enhanced immune cell function was observed at the 75 µg and 100 µg dose levels.

Preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of cemsidomide combined with elranatamab (ELREXFIO®) showed expansion and activation of CD8+

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd I

Fri, 25 Sep 2026 07:00:00 -0400

Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action

Biomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elranatamab Reinforce Cemsidomide’s Ability to Drive T-cell Expansion and Activation, and Prevent T-cell Exhaustion When Combined with Immune-based Therapies

First Cemsidomide Dose Level (75 µg) in Phase 1b Trial with Elranatamab Declared Safe by Safety Data Review Committee; Advancing Trial to Dose Expansion and Escalation Cohorts with Data from All Cohorts Evaluated Expected in Mid-2027

WATERTOWN, Mass., Sept.

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd I

Fri, 25 Sep 2026 07:00:00 -0400

Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action

WATERTOWN, Mass., Sept.

Form 4 C4 Therapeutics, Inc. For: Sep 18 Filed by: Adams Kendra

Mon, 21 Sep 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260921/27085619.html

C4 Therapeutics to present cemsidomide biomarker data at myeloma meeting

Thu, 03 Sep 2026 07:00:50 -0400

C4 Therapeutics, Inc. (Nasdaq: CCCC) announced it will present new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone at the 23rd International Myeloma Society Annual Meeting in Glasgow, Scotland, running September 23–26, 2026.

The data, drawn from the company's Phase 1 trial in relapsed/refractory multiple myeloma, characterize the immune effects on T cells and natural killer cells across once-daily dose levels evaluated in the trial. The findings will be presented in a poster session on September 25, 2026, from 12 pm to 1 pm BST.

The poster, titled "T- And NK-Cell Immunomodulatory Reprogramming By Cemsidomide, A Novel And

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd I

Thu, 03 Sep 2026 07:00:00 -0400

WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23^rd IMS Annual Meeting. The data characterize the immune effects on T cells and natural killer (NK) cells across the once-daily dose levels evaluated in the Phase 1 trial, further supporting cemsidomide’s potential as a combination partner for

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd I

Thu, 03 Sep 2026 07:00:00 -0400

Form 144 C4 Therapeutics, Inc. Filed by: Mossler Mark

Fri, 14 Aug 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26933207.html

Form 144 C4 Therapeutics, Inc. Filed by: Mossler Mark

Fri, 14 Aug 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26933207.html

Form 144 C4 Therapeutics, Inc. Filed by: Geldmacher Jay L

Fri, 14 Aug 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260814/26933171.html

Form 144 C4 Therapeutics, Inc. Filed by: Geldmacher Jay L

Fri, 14 Aug 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260814/26933171.html

Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932106.html

Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932106.html

Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931877.html

Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931877.html

Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: Squadron Capital Management LLC

Fri, 14 Aug 2026 12:54:00 -0400

si-local-file:///var/storage/secattach/20260814/26928087.html

Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: Squadron Capital Management LLC

Fri, 14 Aug 2026 12:54:00 -0400

si-local-file:///var/storage/secattach/20260814/26928087.html

Form 144 C4 Therapeutics, Inc. Filed by: Mossler Mark

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921483.html

Form 144 C4 Therapeutics, Inc. Filed by: Mossler Mark

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921483.html

Form 144 C4 Therapeutics, Inc. Filed by: Mossler Mark

Wed, 12 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26914454.html